Mankind Pharma Limited
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.
What Mankind files
- Others66
- Investor Meet45
- Important38
- Updates35
- Board Meeting18
- JV/Acquisition9
Mankind Pharma delivered strong Q1 FY27 performance, with overall revenue rising 12.9% YoY to 4,031 Cr. EBITDA grew 24.7% to 1,060 Cr, boosting margins by 250 bps to 26.3%. Profit After Tax increased 29.1% to 574 Cr, resulting in a diluted EPS of INR 13.7. Domestic business (ex-Consumer Healthcare) saw...
**1. Business Performance:** Mankind Pharma's Q4 revenue grew 11.8% YoY to INR 3,443 Cr; FY26 revenue rose 17% to INR 14,278 Cr. Q4 profit after tax surged 30.4% YoY to INR 559 Cr, though FY26 profit dipped 3.4%. Domestic business (ex-Consumer Healthcare) grew 13% in Q4, with chronic segment share...
Mankind Pharma reported strong Q3FY26 results with revenue up 11.5% YoY to ₹3,567 Cr and Profit After Tax (PAT) increasing 9.5% to ₹414 Cr. Domestic business grew 11.1% to ₹3,046 Cr, while Exports saw a robust 14.1% jump to ₹521 Cr. Growth is propelled by an increasing chronic share, now...
Here's a concise summary for retail investors: **Business Performance & Key Financial Metrics:** Mankind Pharma posted 20.8% YoY revenue growth to 3,697 Cr in Q2FY26. Domestic sales climbed 14.5% to 3,184 Cr, driven by chronic segment outperformance (Cardiac +1.3x, Anti-diabetics +1.2x vs IPM) and BSV integration. Exports surged 82.6% to...
**Financial Highlights:** Q1 FY26 revenue grew 24.5% YoY to 3,570 Cr. EBITDA reached 850 Cr (+25.8% YoY) with a 23.8% margin. Profit after tax was 445 Cr. Net debt stood at 5,249 Cr. Cash flow from operations converted 99% of EBITDA. An interim dividend was approved. **Strategic Initiatives & Growth...